Which disease courses are commonly treated with disease-modifying therapies in multiple sclerosis?

Which disease courses are commonly treated with disease-modifying therapies in multiple sclerosis?

• A. Clinically isolated syndrome only
• B. Primary progressive MS only
• C. RRMS and SPMS
• D. Secondary progressive MS only

Answer: (C)

Disease-modifying therapies are used to alter the inflammatory activity that drives relapses in multiple sclerosis. The forms of MS where this inflammation-and-relapse pattern is most prominent are relapsing-remitting MS, where attacks come and recover, and secondary progressive MS when there is still inflammatory activity contributing to relapses or progression. In these courses, DMTs can reduce relapse frequency, limit new MRI lesions, and slow disability progression. Primary progressive MS progresses more steadily with less overt inflammatory relapse, so traditional DMTs are not as routinely used there. Clinically isolated syndrome is an initial event that may lead to MS, and while some high-risk CIS patients may be treated to delay conversion, it’s not a distinct relapsing course like RRMS or SPMS. So the best answer is that disease-modifying therapies are commonly used in relapsing-remitting MS and in secondary progressive MS with inflammatory activity.

Disease-modifying therapies are used to alter the inflammatory activity that drives relapses in multiple sclerosis. The forms of MS where this inflammation-and-relapse pattern is most prominent are relapsing-remitting MS, where attacks come and recover, and secondary progressive MS when there is still inflammatory activity contributing to relapses or progression. In these courses, DMTs can reduce relapse frequency, limit new MRI lesions, and slow disability progression.

Primary progressive MS progresses more steadily with less overt inflammatory relapse, so traditional DMTs are not as routinely used there. Clinically isolated syndrome is an initial event that may lead to MS, and while some high-risk CIS patients may be treated to delay conversion, it’s not a distinct relapsing course like RRMS or SPMS. So the best answer is that disease-modifying therapies are commonly used in relapsing-remitting MS and in secondary progressive MS with inflammatory activity.